FDA-approved drug sensitises brain cancer cells to radiotherapy
Drug Discovery World
JANUARY 23, 2023
Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care. As an FDA-approved oral drug, the side-effects of cladribine are quite manageable and it has been well evaluated for pharmacokinetics.
Let's personalize your content